Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development

30 May 2023

Abstract excerpt

CAR T-cell product quality and stemness (Tstem) are major determinants of in vivo expansion, efficacy, and clinical response. Prolonged ex vivo culturing is known to deplete Tstem, affecting clinical outcome. YTB323, a novel autologous CD19-directed CAR T-cell therapy expressing the same validated CAR as tisagenlecleucel, is manufactured using a next-generation platform in <2 days. Here, we report the preclinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Viral Infectious Diseases and Gene Expression in Insects
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37249512
DOI: 10.1158/2159-8290.cd-22-1276

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical DevelopmentPMID 37249512Read ↗

A distinct CAR-T cell phenotype mediates therapeutic response at limited doses.Semantic proximity Read ↗

Advancing CAR T-cell therapies: Preclinical insights and clinical translation for hematological malignanciesSemantic proximity Read ↗

Single-Cell RNA Analysis Reveals Cell-Intrinsic Functions of CAR T Cells Correlating with Response in a Phase II Study of Lymphoma PatientsSemantic proximity Read ↗

Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphomaSemantic proximity Read ↗

Brexucabtagene Autoleucel For Relapsed/Refractory Mantle Cell Lymphoma in Asia: Redefining the Role of Allogeneic Haematopoietic Stem Cell TransplantationSemantic proximity Read ↗

CAR-T-Cell Therapy: Present Progress and Future strategiesSemantic proximity Read ↗

Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma.Semantic proximity Read ↗

Comparative Effectiveness of CAR T-Cell Therapy versus Blinatumomab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A prospective cohort studySemantic proximity Read ↗

Characteristics of premanufacture CD8+ T cells determine CAR-T efficacy in patients with diffuse large B-cell lymphomaSemantic proximity Read ↗

In vivo generation of human CD19‐CAR T cells results in B‐cell depletion and signs of cytokine release syndromeSemantic proximity Read ↗

A Correlation Between Differentiation Phenotypes of Infused T Cells and Anti-Cancer Immunotherapy.Semantic proximity Read ↗

Anti-CD7 allogeneic WU-CART-007 in patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma: a phase 1/2 trialSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.